Objective: Epithelial ovarian cancer (EOC) is usually diagnosed at advanced stages with highly variable clinical outcomes, even among patients with similar clinical characteristics and treatments. Host immune system plays a pivotal role in EOC pathogenesis and progression. Here, we assessed the clinical significance of 192 single nucleotide polymorphisms (SNPs) on 34 immune-system related genes in EOC patients.
Methods: Two hundred and thirty advanced EOC patients treated with platinum-based chemotherapy were included. Germ-line DNA was analyzed with Illumina GoldenGate Genotyping Assay.
Results: Nineteen polymorphisms were significantly associated with overall survival (OS), 17 with progression free survival (PFS) and 20 with platinum-free interval (PFI). Of the 8 polymorphisms associated with all three outcomes, 7 SNPs belonged to genes involved in the TGF-β pathway. A genetic score was built considering the unfavourable genotypes (UGs) of these 7 polymorphisms (group 0-2 UGs: presence of 0, 1, or 2 UGs; group 3-4 UGs: 3 or 4 UGs; group 5-7: 5, 6, or 7 UGs). According to this score, OS decreased as the number of UGs increased (median OS: 0-2 UGs = not reached, 3-4 UGs = 44.6 and 5-7 UGs = 19.3 months, p < 0.0001). The same trend was observed also for PFS (median PFS: 0-2 UGs = 21.5, 3-4 UGs = 17.3 and 5-7 UGs = 11 months, p < 0.0001) and PFI (median PFI: 0-2 UGs = 16.6, 3-4 UGs = 9.8 and 5-7 UGs = 3.8 months, p < 0.0001). The score was validated by permutation analysis.
Conclusions: The proposed TGF-β pathway score could be useful to define prognosis and platinum sensitivity of advanced EOC patients.
Keywords: Immune system; Ovarian cancer; Platinum; Polymorphism; Survival; TGF-β.
Copyright © 2019 Elsevier Inc. All rights reserved.
The Role of Single Nucleotide Polymorphisms of the ERCC1 and MMS19 Genes in Predicting Platinum-Sensitivity, Progression-Free and Overall Survival in Advanced Epithelial Ovarian CancerKM Moxley et al. Gynecol Oncol 130 (2), 377-82. PMID 23632208.Polymorphisms in ERCC1, codon-118 and MMS19 genes are not associated with clinical response to platinum or survival. The ERCC1-C8092A genotypes containing an "A" allele w …
[Polymorphisms of ERCC1 Gene and Outcomes in Epithelial Ovarian Cancer Patients With Platinum-Based Chemotherapy]BL Qi et al. Zhonghua Fu Chan Ke Za Zhi 48 (11), 847-52. PMID 24444563.The rs11615 SNP of ERCC1 may become a valuable prognostic biomarker for EOC patients treated with platinum-based chemotherapy.
Pegylated Liposomal Doxorubicin for Relapsed Epithelial Ovarian CancerTA Lawrie et al. Cochrane Database Syst Rev 2013 (7), CD006910. PMID 23835762. - ReviewIn platinum-sensitive relapsed epithelial ovarian cancer, PLD/carbo is more effective than PAC/carbo and is better tolerated; PLD/carbo should therefore be considered as …
Luteinising Hormone Releasing Hormone (LHRH) Agonists for the Treatment of Relapsed Epithelial Ovarian CancerR Wuntakal et al. Cochrane Database Syst Rev 2016 (6), CD011322. PMID 27356090. - ReviewBased on this review of two small RCTs, there is not enough evidence to comment on the safety and effectiveness of LHRH agonists in the treatment of platinum-refractory a …
Pre-treatment Tumor Expression of ERCC1 in Women With Advanced Stage Epithelial Ovarian Cancer Is Not Predictive of Clinical Outcomes: A Gynecologic Oncology Group StudyJM Rubatt et al. Gynecol Oncol 125 (2), 421-6. PMID 22261301.ERCC1 expression, measured by IHC in pre-treatment tumor specimens, using a highly specific antibody, has limited clinical value in patients with advanced EOC treated wit …